Although there is a relative paucity of preclinical trials that have specifically attempted the delivery of PD-1/PD-L1 ICIs by LDD, existing studies, as we describe below, will likely inspire additional trials and evidence to support future clinical translation of this ICI delivery approach in certain cancer contexts. Here, CD274 is linked to cancer.